PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors

BACKGROUND: The clinical benefit of immunotherapeutic approaches against cancer has been well established although complete responses are only observed in a minority of patients. Combination immunotherapy offers an attractive avenue to develop more effective cancer therapies by improving the efficac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Beyrend, Guillaume, van der Gracht, Esmé, Yilmaz, Ayse, van Duikeren, Suzanne, Camps, Marcel, Höllt, Thomas, Vilanova, Anna, van Unen, Vincent, Koning, Frits, de Miranda, Noel F. C. C., Arens, Ramon, Ossendorp, Ferry
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694641/
https://ncbi.nlm.nih.gov/pubmed/31412943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0700-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados